Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Formica Capital in connection with its acquisition of the Rototec Group, the biggest supplier of geoenergy solutions in Europe
Mandate

Vinge advises Formica Capital in connection with its acquisition of the Rototec Group, the biggest supplier of geoenergy solutions in Europe

November 25, 2021 M&A Banking and Finance

Vinge has advised Formica Capital in connection with its acquisition of all shares in the Rototec Group. Rototec is a market leader in the field of geoenergy solutions for medium and large sized properties and handles Europe’s largest fleet of drilling equipment for geoenergy issues in Finland, Sweden and Norway.

Vinge’s team mainly consisted of Magnus Pauli (M&A), Johanna Hamrefält (Project Manager, M&A), Alexander Lindeberg (IP), Adam Loewenstein (M&A), Malin Olsson (HR), Hanna Marberg (M&A) as well as Fabian Ekeblad (Banking & Finance) and Elin Samara (Banking & Finance). Krogerus Attorneys acted as local counsel in Finland with Advokatfirmaet Thommessen AS acting as local counsel in Norway.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025